|Bid||336.50 x 800|
|Ask||336.99 x 900|
|Day's range||329.39 - 338.60|
|52-week range||65.49 - 497.49|
|Beta (5Y monthly)||1.49|
|PE ratio (TTM)||39.34|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Dr. Elizabeth Clayborne, Adjunct Assistant Professor of Emergency Medicine at the University of Maryland School of Medicine and Emergency Physician at UM Capital Region Medical Center, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.
Moderna (NASDAQ: MRNA) stock might look a bit expensive these days. At the same time, some investors wonder whether Moderna may have reached peak sales of its coronavirus vaccine. Right now, it's too early to predict if and when coronavirus vaccine sales will slow.
Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a stock. Here's why they picked Cassava Sciences (NASDAQ: SAVA), Ocugen (NASDAQ: OCGN), and Moderna (NASDAQ: MRNA). Prosper Junior Bakiny (Cassava Sciences): Investors have been flocking to this clinical-stage biotech all year long, pushing its share price up by well over 600%.